ERBB2 and neoplasm: In vivo NIRF imaging with IRDye800-conjugated trastuzumab and pertuzumab demonstrated clear tumor uptake of the immunoconjugates in HER2-overexpressing BT474 xenografts, whereas minimal signal was detected in MCF7 tumors (Figures 4(a) and 4(b)).